Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers
NCT ID: NCT06987708
Last Updated: 2025-12-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
NA
Total Enrollment
67 participants
Study Classification
INTERVENTIONAL
Study Start Date
2026-02-01
Study Completion Date
2028-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A prospective, pilot study to assess the impact of a 12-month multi-focal lifestyle intervention on myeloma-relevant biomarkers in patients with MGUS or SM. The multimodal lifestyle intervention has six foci that patients will participate in over the course of one-year.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Moving Foward With Myeloma (MFM)
NCT07236502
Multiple Myeloma (MM)
NOT_YET_RECRUITING
NA
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
NCT06055894
Multiple Myeloma, Smoldering
Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance
RECRUITING
NA
Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma
NCT01793051
Myeloma
COMPLETED
PHASE2
Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma Survivors
NCT05142371
Plasma Cell Myeloma
COMPLETED
NA
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
NCT00099047
Monoclonal Gammopathy of Undetermined Significance
Multiple Myeloma
Smoldering Multiple Myeloma
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients with a diagnosis of MGUS or SM who are willing and able to participate in this 12-month multimodal lifestyle approach. Eligible patients include those 18 years of age and older diagnosed with MGUS/SM, ECOG PS 0-2, absence of significant comorbidities, and ability to speak/read/understand English.
The multimodal lifestyle intervention has six foci: Positive cognition \[mindset\], Exercise/movement, Stress Reduction, Social Connection, Emotional Wellbeing, and Nutrition. All programming will take place online to maximize convenience/sustained participation.
The multimodal lifestyle intervention has six foci: Positive cognition \[mindset\], Exercise/movement, Stress Reduction, Social Connection, Emotional Wellbeing, and Nutrition. All programming will take place online to maximize convenience/sustained participation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Monoclonal Gammopathy of Uncertain Significance
Smoldering Myeloma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
PREVENTION
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Multimodal Lifestyle Intervention
Group Type
EXPERIMENTAL
The Multimodal Lifestyle Intervention
Intervention Type
OTHER
The multimodal lifestyle intervention has six foci: positive cognition, exercise/movement, stress reduction, social connection, emotional well-being, and nutrition
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The Multimodal Lifestyle Intervention
The multimodal lifestyle intervention has six foci: positive cognition, exercise/movement, stress reduction, social connection, emotional well-being, and nutrition
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adults 18 years or older.
* Diagnosed with MGUS or SM based on commonly accepted criteria per the
International Multiple Myeloma Working Group (IMWG), defined as follows:
a. For a diagnosis of Smoldering Multiple Myeloma (SM), both criteria must be met: i. Serum monoclonal protein (IgG or IgA) ≥ 30g/L or urinary monoclonal protein ≥ 500mg per 24h and/or clonal bone marrow plasma cells 10-60% ii. Absence of myeloma-defining events or amyloidosis b. For a diagnosis of Non-IgM Monoclonal Gammopathy of Undetermined
Significance (MGUS):
i. Serum monoclonal protein \<30g/L ii. Clonal bone marrow plasma cells \<10% iii. Absence of end-organ damage such as hypercalcemia, renal insufficiency, anemia, and bone lesions (CRAB) or amyloidosis that can be attributed to the plasma cell proliferative disorder c. For a diagnosis of IgM MGUS: i. Serum IgM monoclonal protein \<30g/L ii. No evidence of anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, hepatosplenomegaly, or other end-organ damage that can be attributed to the plasma cell proliferative disorder d. For a diagnosis of light change MGUS: i. Abnormal FLC ratio (\<0.26 or \>1.65) ii. Increased level of the appropriate free light chain (increased κ FLC in patients with ratio \>1.65 and increased λ FLC in patients with ratio \<0.26) iii. No immunoglobulin heavy chain expression on immunofixation iv. Absence of end-organ damage such as hypercalcemia, renal insufficiency, anemia, and bone lesions (CRAB) or amyloidosis that can be attributed to the plasma cell proliferative disorder v. Clonal bone marrow plasma cells \<10% vi. Urinary monoclonal protein \<500mg/24h
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2
* Ability to speak, read and comprehend the English language.
* Absence of significant intercurrent illness such as uncontrolled heart failure, unstable angina, cardiac arrhythmia and psychiatric illness which would preclude informed consent.
* Patient understands the purpose of the trial and procedures required for the trial, and can provide signed informed consent as which includes compliances with the requirements and restrictions listed in the informed consent form (ICF) and in the study protocol.
* Ability to adhere to the study visit schedule and all the protocol requirements, including surveillance imaging and test specimen (blood sample) collection at specified time points.
* Diagnosed with MGUS or SM based on commonly accepted criteria per the
International Multiple Myeloma Working Group (IMWG), defined as follows:
a. For a diagnosis of Smoldering Multiple Myeloma (SM), both criteria must be met: i. Serum monoclonal protein (IgG or IgA) ≥ 30g/L or urinary monoclonal protein ≥ 500mg per 24h and/or clonal bone marrow plasma cells 10-60% ii. Absence of myeloma-defining events or amyloidosis b. For a diagnosis of Non-IgM Monoclonal Gammopathy of Undetermined
Significance (MGUS):
i. Serum monoclonal protein \<30g/L ii. Clonal bone marrow plasma cells \<10% iii. Absence of end-organ damage such as hypercalcemia, renal insufficiency, anemia, and bone lesions (CRAB) or amyloidosis that can be attributed to the plasma cell proliferative disorder c. For a diagnosis of IgM MGUS: i. Serum IgM monoclonal protein \<30g/L ii. No evidence of anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, hepatosplenomegaly, or other end-organ damage that can be attributed to the plasma cell proliferative disorder d. For a diagnosis of light change MGUS: i. Abnormal FLC ratio (\<0.26 or \>1.65) ii. Increased level of the appropriate free light chain (increased κ FLC in patients with ratio \>1.65 and increased λ FLC in patients with ratio \<0.26) iii. No immunoglobulin heavy chain expression on immunofixation iv. Absence of end-organ damage such as hypercalcemia, renal insufficiency, anemia, and bone lesions (CRAB) or amyloidosis that can be attributed to the plasma cell proliferative disorder v. Clonal bone marrow plasma cells \<10% vi. Urinary monoclonal protein \<500mg/24h
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2
* Ability to speak, read and comprehend the English language.
* Absence of significant intercurrent illness such as uncontrolled heart failure, unstable angina, cardiac arrhythmia and psychiatric illness which would preclude informed consent.
* Patient understands the purpose of the trial and procedures required for the trial, and can provide signed informed consent as which includes compliances with the requirements and restrictions listed in the informed consent form (ICF) and in the study protocol.
* Ability to adhere to the study visit schedule and all the protocol requirements, including surveillance imaging and test specimen (blood sample) collection at specified time points.
Exclusion Criteria
* Evidence of any one or more of the following biomarkers of malignancy, or myeloma-defining events (MDEs) meeting IMWG criteria for a diagnosis of multiple myeloma:
1. 60% or greater clonal plasma cells on bone marrow examination
2. Serum involved / uninvolved free light chain ratio of 100 or greater, provided the absolute level of the involved light chain is at least 100mg/L (a patient's involved free light chain either kappa or lambda is the one that is above the normal reference range; the uninvolved free light chain is the one that is typically in, or below, the normal range)
3. More than one focal lesion on MRI that is at least 5mm or greater in size.
* Evidence of end-organ damage as per the IMWG CRAB criteria, defined as follows:
1. Hypercalcemia: serum calcium \>0.25 mmol/L (\>1mg/dL) higher than the upper limit of normal or \>2.75 mmol/L (\>11mg/dL)
2. Renal insufficiency: creatinine clearance \<40 mL per minute or serum creatinine \>177mol/L (\>2mg/dL)
3. Anemia: hemoglobin value of \>20g/L below the lowest limit of normal, or a hemoglobin value \<100g/L
4. Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET/CT. If bone marrow has \<10% clonal plasma cells, more than one bone lesion is required to distinguish from solitary plasmacytoma with minimal marrow involvement
* Unwillingness or inability to follow required intervention behaviors, including any safety issues related to participating in any part of the intervention (e.g., a contraindication to gentle movement/exercise, BMI \<18 kg/m2, etc.).
* Pregnancy or breastfeeding
* Patient has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
1. 60% or greater clonal plasma cells on bone marrow examination
2. Serum involved / uninvolved free light chain ratio of 100 or greater, provided the absolute level of the involved light chain is at least 100mg/L (a patient's involved free light chain either kappa or lambda is the one that is above the normal reference range; the uninvolved free light chain is the one that is typically in, or below, the normal range)
3. More than one focal lesion on MRI that is at least 5mm or greater in size.
* Evidence of end-organ damage as per the IMWG CRAB criteria, defined as follows:
1. Hypercalcemia: serum calcium \>0.25 mmol/L (\>1mg/dL) higher than the upper limit of normal or \>2.75 mmol/L (\>11mg/dL)
2. Renal insufficiency: creatinine clearance \<40 mL per minute or serum creatinine \>177mol/L (\>2mg/dL)
3. Anemia: hemoglobin value of \>20g/L below the lowest limit of normal, or a hemoglobin value \<100g/L
4. Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET/CT. If bone marrow has \<10% clonal plasma cells, more than one bone lesion is required to distinguish from solitary plasmacytoma with minimal marrow involvement
* Unwillingness or inability to follow required intervention behaviors, including any safety issues related to participating in any part of the intervention (e.g., a contraindication to gentle movement/exercise, BMI \<18 kg/m2, etc.).
* Pregnancy or breastfeeding
* Patient has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Center for Cancer Lifestyle Management
UNKNOWN
Sponsor Role
collaborator
Hackensack Meridian Health
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Siegel, MD
Role: PRINCIPAL_INVESTIGATOR
Hackensack Meridian Health
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Jurisic V, Colovic M. Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma. Med Oncol. 2002;19(3):133-9. doi: 10.1385/MO:19:3:133.
Reference Type
BACKGROUND
Shapiro-Shelef M, Calame K. Plasma cell differentiation and multiple myeloma. Curr Opin Immunol. 2004 Apr;16(2):226-34. doi: 10.1016/j.coi.2004.02.001.
Reference Type
BACKGROUND
Tian T, Wang M, Ma D. TNF-alpha, a good or bad factor in hematological diseases? Stem Cell Investig. 2014 Jun 1;1:12. doi: 10.3978/j.issn.2306-9759.2014.04.02. eCollection 2014.
Reference Type
BACKGROUND
Vignjevic Petrinovic S, Milosevic MS, Markovic D, Momcilovic S. Interplay between stress and cancer-A focus on inflammation. Front Physiol. 2023 Mar 20;14:1119095. doi: 10.3389/fphys.2023.1119095. eCollection 2023.
Reference Type
BACKGROUND
Dhabhar FS. Effects of stress on immune function: the good, the bad, and the beautiful. Immunol Res. 2014 May;58(2-3):193-210. doi: 10.1007/s12026-014-8517-0.
Reference Type
BACKGROUND
Gervas J, Pocovi M, Giraldo P. Proinflammatory Cytokines Profile in Monoclonal Gammopathies Related to Pathogenesis of Bone Disease. Blood. 2009;114(22):4913-4913. doi:10.1182/blood.V114.22.4913.4913
Reference Type
BACKGROUND
Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw. 1999 Mar;10(1):65-70.
Reference Type
BACKGROUND
Mateos MV, Landgren O. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. Cancer Treat Res. 2016;169:3-12. doi: 10.1007/978-3-319-40320-5_1.
Reference Type
BACKGROUND
Plano F, Corsale AM, Gigliotta E, Camarda G, Vullo C, Di Simone M, Shekarkar Azgomi M, Speciale M, Carlisi M, Caccamo N, Dieli F, Meraviglia S, Siragusa S, Botta C. Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again. Hematol Rep. 2023 Jan 9;15(1):23-49. doi: 10.3390/hematolrep15010004.
Reference Type
BACKGROUND
Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, Kota V, Ajebo GH. Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel). 2021 Jan 20;9(1):3. doi: 10.3390/medsci9010003.
Reference Type
BACKGROUND
Cancer.Org. Published 2012. Https://Www.Cancer.Org/Cancer/Multiple-Myeloma/Detectiondiagnosis-Staging/Surviva l-Rates.Html. Accessed January 19, 2023.
Reference Type
BACKGROUND
Multiple Myeloma - Statistics. Cancer.Net. Published February 28, 2019. Https://Www.Cancer.Net/Cancer-Types/Multiple-Myeloma/Statistics. Accessed January 19, 2023.
Reference Type
BACKGROUND
Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ 3rd, Rajkumar SV. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007 Jun 21;356(25):2582-90. doi: 10.1056/NEJMoa070389.
Reference Type
BACKGROUND
Mateos MV, Kumar S, Dimopoulos MA, Gonzalez-Calle V, Kastritis E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, Geraldes C, Gozzetti A, Kyriakou C, Garderet L, Hansson M, Zamagni E, Fantl D, Leleu X, Kim BS, Esteves G, Ludwig H, Usmani S, Min CK, Qi M, Ukropec J, Weiss BM, Rajkumar SV, Durie BGM, San-Miguel J. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020 Oct 16;10(10):102. doi: 10.1038/s41408-020-00366-3.
Reference Type
BACKGROUND
Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame R, Kourelis TV, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Adv. 2018 Nov 27;2(22):3149-3154. doi: 10.1182/bloodadvances.2018024794.
Reference Type
BACKGROUND
Chang SH, Gumbel J, Luo S, Thomas TS, Sanfilippo KM, Luo J, Colditz GA, Carson KR. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. Cancer Epidemiol Biomarkers Prev. 2019 Dec;28(12):2055-2061. doi: 10.1158/1055-9965.EPI-19-0132. Epub 2019 Sep 9.
Reference Type
BACKGROUND
Shapiro YN, Peppercorn JM, Yee AJ, Branagan AR, Raje NS, Donnell EKO. Lifestyle considerations in multiple myeloma. Blood Cancer J. 2021 Oct 26;11(10):172. doi: 10.1038/s41408-021-00560-x.
Reference Type
BACKGROUND
Lee DH, Fung TT, Tabung FK, Marinac CR, Devore EE, Rosner BA, Ghobrial IM, Colditz GA, Giovannucci EL, Birmann BM. Prediagnosis dietary pattern and survival in patients with multiple myeloma. Int J Cancer. 2020 Oct 1;147(7):1823-1830. doi: 10.1002/ijc.32928. Epub 2020 Feb 28.
Reference Type
BACKGROUND
Lee DH, Fung TT, Tabung FK, Colditz GA, Ghobrial IM, Rosner BA, Giovannucci EL, Birmann BM. Dietary Pattern and Risk of Multiple Myeloma in Two Large Prospective US Cohort Studies. JNCI Cancer Spectr. 2019 Jun;3(2):pkz025. doi: 10.1093/jncics/pkz025. Epub 2019 Apr 27.
Reference Type
BACKGROUND
Aggarwal V, Kashyap D, Sak K, Tuli HS, Jain A, Chaudhary A, Garg VK, Sethi G, Yerer MB. Molecular Mechanisms of Action of Tocotrienols in Cancer: Recent Trends and Advancements. Int J Mol Sci. 2019 Feb 2;20(3):656. doi: 10.3390/ijms20030656.
Reference Type
BACKGROUND
Gong IY, Cheung MC, Read S, Na Y, Lega IC, Lipscombe LL. Association between diabetes and haematological malignancies: a population-based study. Diabetologia. 2021 Mar;64(3):540-551. doi: 10.1007/s00125-020-05338-7. Epub 2021 Jan 6.
Reference Type
BACKGROUND
Parikh R, Tariq SM, Marinac CR, Shah UA. A comprehensive review of the impact of obesity on plasma cell disorders. Leukemia. 2022 Feb;36(2):301-314. doi: 10.1038/s41375-021-01443-7. Epub 2021 Oct 15.
Reference Type
BACKGROUND
Hodge A, Sheean P, O'Connor P, Tyler K, Kerschner A, Williams A, Jensik K, Visotcky A, D'Souza A, Hari P, Dhakal B, Chhabra S, Flynn KE, Hagen P, Stolley M. Exploring health behaviors and the feasibility of a lifestyle intervention for patients with multiple myeloma. Support Care Cancer. 2022 Dec;30(12):9771-9779. doi: 10.1007/s00520-022-07385-9. Epub 2022 Oct 26.
Reference Type
BACKGROUND
Storti P, Agnelli L, Palma BD, Todoerti K, Marchica V, Accardi F, Sammarelli G, Deluca F, Toscani D, Costa F, Vicario E, Todaro G, Martella E, Neri A, Giuliani N. The transcriptomic profile of CD138+ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged. Haematologica. 2019 Oct;104(10):e465-e469. doi: 10.3324/haematol.2018.209999. Epub 2019 Mar 7. No abstract available.
Reference Type
BACKGROUND
Boyle EM, Deshpande S, Tytarenko R, Ashby C, Wang Y, Bauer MA, Johnson SK, Wardell CP, Thanendrarajan S, Zangari M, Facon T, Dumontet C, Barlogie B, Arbini A, Rustad EH, Maura F, Landgren O, Zhan F, van Rhee F, Schinke C, Davies FE, Morgan GJ, Walker BA. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nat Commun. 2021 Jan 12;12(1):293. doi: 10.1038/s41467-020-20524-2.
Reference Type
BACKGROUND
Madhira BR, Konala VM, Adapa S, Naramala S, Ravella PM, Parikh K, Gentile TC. Recent Advances in the Management of Smoldering Multiple Myeloma. World J Oncol. 2020 Apr;11(2):45-54. doi: 10.14740/wjon1245. Epub 2020 Mar 29.
Reference Type
BACKGROUND
Kim EB, Yee AJ, Raje N. Treatment of Smoldering Multiple Myeloma: Ready for Prime Time? Cancers (Basel). 2020 May 13;12(5):1223. doi: 10.3390/cancers12051223.
Reference Type
BACKGROUND
Romano A, Cerchione C, Conticello C, Martinelli G, Di Raimondo F. How we manage smoldering multiple myeloma. Hematol Rep. 2020 Sep 21;12(Suppl 1):8951. doi: 10.4081/hr.2020.8951. eCollection 2020 Sep 21.
Reference Type
BACKGROUND
San Miguel J, Mateos MV, Gonzalez V, et al. Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. J Clin Oncol. 2019;37(15_suppl):8000-8000. doi:10.1200/JCO.2019.37.15_suppl.8000
Reference Type
BACKGROUND
Ho M, Patel A, Goh CY, Moscvin M, Zhang L, Bianchi G. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia. 2020 Dec;34(12):3111-3125. doi: 10.1038/s41375-020-01051-x. Epub 2020 Oct 12.
Reference Type
BACKGROUND
Boen CE, Barrow DA, Bensen JT, Farnan L, Gerstel A, Hendrix LH, Yang YC. Social Relationships, Inflammation, and Cancer Survival. Cancer Epidemiol Biomarkers Prev. 2018 May;27(5):541-549. doi: 10.1158/1055-9965.EPI-17-0836. Epub 2018 Feb 23.
Reference Type
BACKGROUND
Shah UA, Alicea D, Adintori PA, et al. A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study. Blood. 2021;138(Supplement 1):4759-4759. doi:10.1182/blood-2021-151049
Reference Type
BACKGROUND
Shah UA, Parikh R, Castro F, Bellone M, Lesokhin AM. Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders. Leukemia. 2023 May;37(5):964-980. doi: 10.1038/s41375-023-01874-4. Epub 2023 Mar 30.
Reference Type
BACKGROUND
Shah UA, Maclachlan KH, Derkach A, Salcedo M, Barnett K, Caple J, Blaslov J, Tran L, Ciardiello A, Burge M, Shekarkhand T, Adintori P, Cross J, Pianko MJ, Hosszu K, McAvoy D, Mailankody S, Korde N, Hultcrantz M, Hassoun H, Tan CR, Lu SX, Patel D, Diamond B, Shah G, Scordo M, Lahoud O, Chung DJ, Landau H, Usmani SZ, Giralt S, Taur Y, Landgren CO, Block G, Block T, Peled JU, van den Brink MRM, Lesokhin AM. Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets. Clin Cancer Res. 2022 Dec 1;28(23):5149-5155. doi: 10.1158/1078-0432.CCR-22-0723.
Reference Type
BACKGROUND
Brevi A, Cogrossi LL, Lorenzoni M, Mattorre B, Bellone M. The Insider: Impact of the Gut Microbiota on Cancer Immunity and Response to Therapies in Multiple Myeloma. Front Immunol. 2022 Mar 17;13:845422. doi: 10.3389/fimmu.2022.845422. eCollection 2022.
Reference Type
BACKGROUND
Groeneveldt L, Mein G, Garrod R, Jewell AP, Van Someren K, Stephens R, D'Sa SP, Yong KL. A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors. BMC Cancer. 2013 Jan 24;13:31. doi: 10.1186/1471-2407-13-31.
Reference Type
BACKGROUND
Jones LW, Eves ND, Waner E, Joy AA. Exercise therapy across the lung cancer continuum. Curr Oncol Rep. 2009 Jul;11(4):255-62. doi: 10.1007/s11912-009-0036-0.
Reference Type
BACKGROUND
Zheng A, Zhang L, Yang J, Yin X, Zhang T, Wu X, Ma X. Physical activity prevents tumor metastasis through modulation of immune function. Front Pharmacol. 2022 Oct 12;13:1034129. doi: 10.3389/fphar.2022.1034129. eCollection 2022.
Reference Type
BACKGROUND
Sitlinger A, Brander DM, Bartlett DB. Impact of exercise on the immune system and outcomes in hematologic malignancies. Blood Adv. 2020 Apr 28;4(8):1801-1811. doi: 10.1182/bloodadvances.2019001317.
Reference Type
BACKGROUND
Baldelli G, De Santi M, Gervasi M, Annibalini G, Sisti D, Hojman P, Sestili P, Stocchi V, Barbieri E, Brandi G. The effects of human sera conditioned by high-intensity exercise sessions and training on the tumorigenic potential of cancer cells. Clin Transl Oncol. 2021 Jan;23(1):22-34. doi: 10.1007/s12094-020-02388-6. Epub 2020 May 23.
Reference Type
BACKGROUND
Sitlinger A, Deal MA, Garcia E, Connelly M, Thompson D, Stewart T, Macdonald G, Hanson ED, Neely M, Neely B, Artese A, Weinberg JB, Brander D, Bartlett DB. Associations of clinical and circulating metabolic biomarkers with low physical fitness and function in adults with chronic lymphocytic leukemia. Front Oncol. 2022 Aug 3;12:933619. doi: 10.3389/fonc.2022.933619. eCollection 2022.
Reference Type
BACKGROUND
Wang J, Sheng L, Lai Y, Ouyang G, Xu Z. Effects of physical activity on clinical and inflammatory markers in diagnosing multiple myeloma patients. Front Physiol. 2023 Jan 4;13:1094470. doi: 10.3389/fphys.2022.1094470. eCollection 2022.
Reference Type
BACKGROUND
Lecat CSY, McCourt O, Land J, Yong K, Fisher A. Multiple myeloma and physical activity. BMC Res Notes. 2021 May 7;14(1):171. doi: 10.1186/s13104-021-05591-y.
Reference Type
BACKGROUND
Hillengass M, Joseph J, Mccarthy J, Hillengass J. Physical Activity in Multiple Myeloma: A Review of the Current Literature. J Adv Pract Oncol. 2023 Mar;14(2):153-158. doi: 10.6004/jadpro.2023.14.2.5. Epub 2023 Mar 1.
Reference Type
BACKGROUND
Joseph JM, Hillengass M, Jacobson H, et al. Immune Markers of Multiple Myeloma Patients Demonstrate Significant Change after Participation in Six-Month Physical Activity Intervention. Blood. 2022;140(Supplement 1):12630-12632. doi:10.1182/blood-2022-167655
Reference Type
BACKGROUND
Roswell Park Cancer Institute. Strength Training in Improving Pain and Quality of Life in Patients With Multiple Myeloma. ClinicalTrials.Gov Identifier: NCT03793907. Updated April 10, 2023. Accessed May 19, 2023. Https://Clinicaltrials.Gov/Ct2/Show/NCT03793907
Reference Type
BACKGROUND
Hillengass J, Hillengass M, Sweeney NW, et al. Physical Activity in Patients with Monoclonal Gammopathies - a Healthtree Cure Hub Study. Blood. 2022;140(Supplement 1):7136-7137. doi:10.1182/blood-2022-162327
Reference Type
BACKGROUND
Seefried L, Genest F, Stromsdorfer J, Engelmann B, Lapa C, Jakob F, Baumann FT, Sperlich B, Jundt F. Impact of whole-body vibration exercise on physical performance and bone turnover in patients with monoclonal gammopathy of undetermined significance. J Bone Oncol. 2020 Sep 28;25:100323. doi: 10.1016/j.jbo.2020.100323. eCollection 2020 Dec.
Reference Type
BACKGROUND
Strasser F, Palmer JL, Schover LR, Yusuf SW, Pisters K, Vassilopoulou-Sellin R, DeGracia B, Willey JS, Bruera E. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer. 2006 Dec 15;107(12):2949-57. doi: 10.1002/cncr.22339.
Reference Type
BACKGROUND
Walsh D, Nelson KA. Autonomic nervous system dysfunction in advanced cancer. Support Care Cancer. 2002 Oct;10(7):523-8. doi: 10.1007/s00520-002-0376-x. Epub 2002 Aug 22.
Reference Type
BACKGROUND
Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, Frenette PS. Autonomic nerve development contributes to prostate cancer progression. Science. 2013 Jul 12;341(6142):1236361. doi: 10.1126/science.1236361.
Reference Type
BACKGROUND
De Couck M, Caers R, Spiegel D, Gidron Y. The Role of the Vagus Nerve in Cancer Prognosis: A Systematic and a Comprehensive Review. J Oncol. 2018 Jul 2;2018:1236787. doi: 10.1155/2018/1236787. eCollection 2018.
Reference Type
BACKGROUND
Yang EV. Role for catecholamines in tumor progression: possible use for beta-blockers in the treatment of cancer. Cancer Biol Ther. 2010 Jul 1;10(1):30-2. doi: 10.4161/cbt.10.1.12260. Epub 2010 Jul 6. No abstract available.
Reference Type
BACKGROUND
Hanns P, Paczulla AM, Medinger M, Konantz M, Lengerke C. Stress and catecholamines modulate the bone marrow microenvironment to promote tumorigenesis. Cell Stress. 2019 Jun 4;3(7):221-235. doi: 10.15698/cst2019.07.192.
Reference Type
BACKGROUND
Yang EV, Benson DM, Glaser R. Catecholamines can mediate stress-related effects on tumor progression. Expert Rev Endocrinol Metab. 2008 Nov;3(6):699-703. doi: 10.1586/17446651.3.6.699.
Reference Type
BACKGROUND
Deguchi A. Curcumin targets in inflammation and cancer. Endocr Metab Immune Disord Drug Targets. 2015;15(2):88-96. doi: 10.2174/1871530315666150316120458.
Reference Type
BACKGROUND
Zhou X, Ma Z, Zhang L, Zhou S, Wang J, Wang B, Fu W. Heart rate variability in the prediction of survival in patients with cancer: A systematic review and meta-analysis. J Psychosom Res. 2016 Oct;89:20-5. doi: 10.1016/j.jpsychores.2016.08.004. Epub 2016 Aug 8.
Reference Type
BACKGROUND
Hanoun M, Maryanovich M, Arnal-Estape A, Frenette PS. Neural regulation of hematopoiesis, inflammation, and cancer. Neuron. 2015 Apr 22;86(2):360-73. doi: 10.1016/j.neuron.2015.01.026.
Reference Type
BACKGROUND
Cheng Y, Sun F, D'Souza A, Dhakal B, Pisano M, Chhabra S, Stolley M, Hari P, Janz S. Autonomic nervous system control of multiple myeloma. Blood Rev. 2021 Mar;46:100741. doi: 10.1016/j.blre.2020.100741. Epub 2020 Aug 11.
Reference Type
BACKGROUND
Zhang L, Pan J, Chen W, Jiang J, Huang J. Chronic stress-induced immune dysregulation in cancer: implications for initiation, progression, metastasis, and treatment. Am J Cancer Res. 2020 May 1;10(5):1294-1307. eCollection 2020.
Reference Type
BACKGROUND
Finkelstein-Fox L, Denninger JW, Walsh LE, Laubach JP, Yee AJ, O'Donnell E, Macklin EA, Gu X, Muzikansky A, Libermann TA, Nicolosi G, Richardson PG, Raje NS, Fricchione GL, Perez GK, Traeger LN, Chad-Friedman E, Park ER. Psychosocial and NF-kappaB Activity Effects of the Stress Management and Resiliency Training: Relaxation Response Resiliency Program (SMART-3RP) on Patients With MGUS and Smoldering Multiple Myeloma: A Randomized Waitlist Control Trial. Psychooncology. 2025 Jul;34(7):e70216. doi: 10.1002/pon.70216.
Reference Type
BACKGROUND
Maatouk I, He S, Hummel M, Hemmer S, Hillengass M, Goldschmidt H, Hartmann M, Herzog W, Hillengass J. Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma. Blood Cancer J. 2019 Jan 21;9(2):9. doi: 10.1038/s41408-019-0172-1. No abstract available.
Reference Type
BACKGROUND
Wang YH, Li JQ, Shi JF, Que JY, Liu JJ, Lappin JM, Leung J, Ravindran AV, Chen WQ, Qiao YL, Shi J, Lu L, Bao YP. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol Psychiatry. 2020 Jul;25(7):1487-1499. doi: 10.1038/s41380-019-0595-x. Epub 2019 Nov 19.
Reference Type
BACKGROUND
Maatouk I, He S, Becker N, Hummel M, Hemmer S, Hillengass M, Goldschmidt H, Hartmann M, Schellberg D, Herzog W, Hillengass J. Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study. BMJ Open. 2018 Jul 30;8(7):e021376. doi: 10.1136/bmjopen-2017-021376.
Reference Type
BACKGROUND
Kroenke CH, Michael YL, Poole EM, Kwan ML, Nechuta S, Leas E, Caan BJ, Pierce J, Shu XO, Zheng Y, Chen WY. Postdiagnosis social networks and breast cancer mortality in the After Breast Cancer Pooling Project. Cancer. 2017 Apr 1;123(7):1228-1237. doi: 10.1002/cncr.30440. Epub 2016 Dec 12.
Reference Type
BACKGROUND
Terao T, Tsushima T, Miura D, Narita K, Takeuchi M, Matsue K. Social frailty predicts worse outcomes in patients with multiple myeloma: A novelty in an old approach. EJHaem. 2020 Jun 17;1(1):103-112. doi: 10.1002/jha2.40. eCollection 2020 Jul.
Reference Type
BACKGROUND
Seyfried TN, Flores RE, Poff AM, D'Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis. 2014 Mar;35(3):515-27. doi: 10.1093/carcin/bgt480. Epub 2013 Dec 16.
Reference Type
BACKGROUND
Le A, Udupa S, Zhang C. The Metabolic Interplay between Cancer and Other Diseases. Trends Cancer. 2019 Dec;5(12):809-821. doi: 10.1016/j.trecan.2019.10.012. Epub 2019 Nov 21.
Reference Type
BACKGROUND
Ragbourne SC, Maghsoodi N, Streetly M, Crook MA. The Association between Metabolic Syndrome and Multiple Myeloma. Acta Haematol. 2021;144(1):24-33. doi: 10.1159/000505992. Epub 2020 May 14.
Reference Type
BACKGROUND
Gavriatopoulou M, Paschou SA, Ntanasis-Stathopoulos I, Dimopoulos MA. Metabolic Disorders in Multiple Myeloma. Int J Mol Sci. 2021 Oct 22;22(21):11430. doi: 10.3390/ijms222111430.
Reference Type
BACKGROUND
Georgakopoulou R, Andrikopoulou A, Sergentanis TN, Fiste O, Zagouri F, Gavriatopoulou M, Psaltopoulou T, Kastritis E, Terpos E, Dimopoulos MA. Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance. Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):361-367. doi: 10.1016/j.clml.2021.01.008. Epub 2021 Jan 15.
Reference Type
BACKGROUND
Chang SH, Luo S, Thomas TS, O'Brian KK, Colditz GA, Carlsson NP, Carson KR. Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study. J Natl Cancer Inst. 2016 Dec 31;109(5):djw264. doi: 10.1093/jnci/djw264. Print 2017 May.
Reference Type
BACKGROUND
Markus E, Trestman S, Cohen Y, Angel Y, Sofer Y, Mittelman M, Avivi I, Stern N, Izkhakov E. Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma. BMC Cancer. 2020 May 30;20(1):489. doi: 10.1186/s12885-020-06976-1.
Reference Type
BACKGROUND
Morris EV, Edwards CM. Adipokines, adiposity, and bone marrow adipocytes: Dangerous accomplices in multiple myeloma. J Cell Physiol. 2018 Dec;233(12):9159-9166. doi: 10.1002/jcp.26884. Epub 2018 Jun 26.
Reference Type
BACKGROUND
Shen Y, Wang C, Wang Y, Lu J, Chen L, Zhang L, Lu W, Zhu W, Hu G, Xia T, Zhou J. Association between time in range and cancer mortality among patients with type 2 diabetes: a prospective cohort study. Chin Med J (Engl). 2021 Sep 15;135(3):288-294. doi: 10.1097/CM9.0000000000001740.
Reference Type
BACKGROUND
Gabbay MAL, Rodacki M, Calliari LE, Vianna AGD, Krakauer M, Pinto MS, Reis JS, Punales M, Miranda LG, Ramalho AC, Franco DR, Pedrosa HPC. Time in range: a new parameter to evaluate blood glucose control in patients with diabetes. Diabetol Metab Syndr. 2020 Mar 16;12:22. doi: 10.1186/s13098-020-00529-z. eCollection 2020.
Reference Type
BACKGROUND
Golombick T, Diamond TH, Manoharan A, Ramakrishna R. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. Am J Hematol. 2012 May;87(5):455-60. doi: 10.1002/ajh.23159. Epub 2012 Apr 4.
Reference Type
BACKGROUND
Golombick T, Diamond TH, Badmaev V, Manoharan A, Ramakrishna R. The potential role of curcumin in patients with monoclonal gammopathy of undefined significance--its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker. Clin Cancer Res. 2009 Sep 15;15(18):5917-22. doi: 10.1158/1078-0432.CCR-08-2217. Epub 2009 Sep 8.
Reference Type
BACKGROUND
Mirzaei H, Bagheri H, Ghasemi F, Khoi JM, Pourhanifeh MH, Heyden YV, Mortezapour E, Nikdasti A, Jeandet P, Khan H, Sahebkar A. Anti-Cancer Activity of Curcumin on Multiple Myeloma. Anticancer Agents Med Chem. 2021;21(5):575-586. doi: 10.2174/1871520620666200918113625.
Reference Type
BACKGROUND
Santosa D, Suharti C, Riwanto I, Dharmana E, Pangarsa EA, Setiawan B, Suyono S, Tobing ML, Suhartono S, Hadisapurto S. Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial. Caspian J Intern Med. 2022 Spring;13(2):375-384. doi: 10.22088/cjim.13.2.9.
Reference Type
BACKGROUND
Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Zangari M, Dhodapkar M, Shaughnessy JD Jr. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007 Feb 15;109(4):1692-700. doi: 10.1182/blood-2006-07-037077. Epub 2006 Oct 5.
Reference Type
BACKGROUND
Kierkegaard-Brøchner S, Sørensen UM, Lange LB, Mortensen LS, Bruun JM. The outcome of a multicomponent lifestyle intervention in patients with obesity: A cohort study. Eur J IntegrMed. 2023;60:102259. doi:10.1016/j.eujim.2023.102259
Reference Type
BACKGROUND
Wong VW, Ho FY, Shi NK, Sarris J, Chung KF, Yeung WF. Lifestyle medicine for depression: A meta-analysis of randomized controlled trials. J Affect Disord. 2021 Apr 1;284:203-216. doi: 10.1016/j.jad.2021.02.012. Epub 2021 Feb 5.
Reference Type
BACKGROUND
Wong VW, Ho FY, Shi NK, Sarris J, Ng CH, Tam OK. Lifestyle medicine for anxiety symptoms: A meta-analysis of randomized controlled trials. J Affect Disord. 2022 Aug 1;310:354-368. doi: 10.1016/j.jad.2022.04.151. Epub 2022 May 3.
Reference Type
BACKGROUND
Abbott S, Smith E, Tighe B, Lycett D. Group versus one-to-one multi-component lifestyle interventions for weight management: a systematic review and meta-analysis of randomised controlled trials. J Hum Nutr Diet. 2021 Jun;34(3):485-493. doi: 10.1111/jhn.12853. Epub 2020 Dec 28.
Reference Type
BACKGROUND
van Namen M, Prendergast L, Peiris C. Supervised lifestyle intervention for people with metabolic syndrome improves outcomes and reduces individual risk factors of metabolic syndrome: A systematic review and meta-analysis. Metabolism. 2019 Dec;101:153988. doi: 10.1016/j.metabol.2019.153988. Epub 2019 Oct 28.
Reference Type
BACKGROUND
Elvsaas IKO, Giske L, Fure B, Juvet LK. Multicomponent Lifestyle Interventions for Treating Overweight and Obesity in Children and Adolescents: A Systematic Review and Meta-Analyses. J Obes. 2017;2017:5021902. doi: 10.1155/2017/5021902. Epub 2017 Dec 17.
Reference Type
BACKGROUND
Petrogianni M, Kanellakis S, Kallianioti K, Argyropoulou D, Pitsavos C, Manios Y. A multicomponent lifestyle intervention produces favourable changes in diet quality and cardiometabolic risk indices in hypercholesterolaemic adults. J Hum Nutr Diet. 2013 Dec;26(6):596-605. doi: 10.1111/jhn.12041. Epub 2013 Mar 20.
Reference Type
BACKGROUND
Goyer L, Dufour R, Janelle C, Blais C, L'Abbe C, Raymond E, de Champlain J, Larochelle P. Randomized controlled trial on the long-term efficacy of a multifaceted, interdisciplinary lifestyle intervention in reducing cardiovascular risk and improving lifestyle in patients at risk of cardiovascular disease. J Behav Med. 2013 Apr;36(2):212-24. doi: 10.1007/s10865-012-9407-3. Epub 2012 Mar 9.
Reference Type
BACKGROUND
Golubic M, Schneeberger D, Kirkpatrick K, Bar J, Bernstein A, Weems F, Ehrman J, Perko J, Doyle J, Roizen M. Comprehensive Lifestyle Modification Intervention to Improve Chronic Disease Risk Factors and Quality of Life in Cancer Survivors. J Altern Complement Med. 2018 Nov;24(11):1085-1091. doi: 10.1089/acm.2018.0193. Epub 2018 Aug 1.
Reference Type
BACKGROUND
Ricanati EH, Golubic M, Yang D, Saager L, Mascha EJ, Roizen MF. Mitigating preventable chronic disease: Progress report of the Cleveland Clinic's Lifestyle 180 program. Nutr Metab (Lond). 2011 Nov 23;8:83. doi: 10.1186/1743-7075-8-83.
Reference Type
BACKGROUND
Innao V, Allegra A, Ginaldi L, Pioggia G, De Martinis M, Musolino C, Gangemi S. Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies. Int J Mol Sci. 2021 May 6;22(9):4922. doi: 10.3390/ijms22094922.
Reference Type
BACKGROUND
Gile JJ, Lopez CL, Ruan GJ, Hathcock MA, Abeykoon JP, Heimgartner JR, Baumann NA, McMahon MM, Micallef IN, Johnston PB, Bisneto JCV, Porrata LF, Paludo J, Ansell SM, Hogan WJ, Witzig TE. Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure. Blood Cancer J. 2021 Mar 26;11(3):65. doi: 10.1038/s41408-021-00452-0.
Reference Type
BACKGROUND
Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood. 2003 Feb 1;101(3):1053-62. doi: 10.1182/blood-2002-05-1320. Epub 2002 Sep 5.
Reference Type
BACKGROUND
Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, Boyd KA, Craig N, French DP, McIntosh E, Petticrew M, Rycroft-Malone J, White M, Moore L. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. BMJ. 2021 Sep 30;374:n2061. doi: 10.1136/bmj.n2061.
Reference Type
BACKGROUND
Klaic M, Kapp S, Hudson P, Chapman W, Denehy L, Story D, Francis JJ. Implementability of healthcare interventions: an overview of reviews and development of a conceptual framework. Implement Sci. 2022 Jan 27;17(1):10. doi: 10.1186/s13012-021-01171-7.
Reference Type
BACKGROUND
Paynter C, McDonald C, Story D, Francis JJ. Application of the theoretical framework of acceptability in a surgical setting: Theoretical and methodological insights. Br J Health Psychol. 2023 Nov;28(4):1153-1168. doi: 10.1111/bjhp.12677. Epub 2023 Jun 24.
Reference Type
BACKGROUND
Coleman EA, Coon S, Hall-Barrow J, Richards K, Gaylor D, Stewart B. Feasibility of exercise during treatment for multiple myeloma. Cancer Nurs. 2003 Oct;26(5):410-9. doi: 10.1097/00002820-200310000-00012.
Reference Type
BACKGROUND
Larsen RF, Jarden M, Minet LR, Frolund UC, Abildgaard N. Supervised and home-based physical exercise in patients newly diagnosed with multiple myeloma-a randomized controlled feasibility study. Pilot Feasibility Stud. 2019 Nov 12;5:130. doi: 10.1186/s40814-019-0518-2. eCollection 2019.
Reference Type
BACKGROUND
Lavery JA, Boutros PC, Knight D, Tammela T, Moskowitz CS, Jones LW. Association of exercise with pan-cancer incidence and overall survival. Cancer Cell. 2024 Feb 12;42(2):169-171. doi: 10.1016/j.ccell.2023.12.007. Epub 2024 Jan 4.
Reference Type
BACKGROUND
Coleman EA, Coon SK, Kennedy RL, Lockhart KD, Stewart CB, Anaissie EJ, Barlogie B. Effects of exercise in combination with epoetin alfa during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for multiple myeloma. Oncol Nurs Forum. 2008 May;35(3):E53-61. doi: 10.1188/08.ONF.E53-E61.
Reference Type
BACKGROUND
Sheinboim D, Parikh S, Manich P, Markus I, Dahan S, Parikh R, Stubbs E, Cohen G, Zemser-Werner V, Bell RE, Ruiz SA, Percik R, Brenner R, Leibou S, Vaknine H, Arad G, Gerber Y, Keinan-Boker L, Shimony T, Bikovski L, Goldstein N, Constantini K, Labes S, Mordechai S, Doron H, Lonescu A, Ziv T, Nizri E, Choshen G, Eldar-Finkelman H, Tabach Y, Helman A, Ben-Eliyahu S, Erez N, Perlson E, Geiger T, Ben-Zvi D, Khaled M, Gepner Y, Levy C. An Exercise-Induced Metabolic Shield in Distant Organs Blocks Cancer Progression and Metastatic Dissemination. Cancer Res. 2022 Nov 15;82(22):4164-4178. doi: 10.1158/0008-5472.CAN-22-0237.
Reference Type
BACKGROUND
Zheng G, Qiu P, Xia R, Lin H, Ye B, Tao J, Chen L. Effect of Aerobic Exercise on Inflammatory Markers in Healthy Middle-Aged and Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Aging Neurosci. 2019 Apr 26;11:98. doi: 10.3389/fnagi.2019.00098. eCollection 2019.
Reference Type
BACKGROUND
Dimitrov S, Hulteng E, Hong S. Inflammation and exercise: Inhibition of monocytic intracellular TNF production by acute exercise via beta2-adrenergic activation. Brain Behav Immun. 2017 Mar;61:60-68. doi: 10.1016/j.bbi.2016.12.017. Epub 2016 Dec 21.
Reference Type
BACKGROUND
Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol. 2011 Aug 5;11(9):607-15. doi: 10.1038/nri3041.
Reference Type
BACKGROUND
Nery C, Moraes SRA, Novaes KA, Bezerra MA, Silveira PVC, Lemos A. Effectiveness of resistance exercise compared to aerobic exercise without insulin therapy in patients with type 2 diabetes mellitus: a meta-analysis. Braz J Phys Ther. 2017 Nov-Dec;21(6):400-415. doi: 10.1016/j.bjpt.2017.06.004. Epub 2017 Jul 5.
Reference Type
BACKGROUND
Magkos F, Tsekouras Y, Kavouras SA, Mittendorfer B, Sidossis LS. Improved insulin sensitivity after a single bout of exercise is curvilinearly related to exercise energy expenditure. Clin Sci (Lond). 2008 Jan;114(1):59-64. doi: 10.1042/CS20070134.
Reference Type
BACKGROUND
Franczyk B, Gluba-Brzozka A, Cialkowska-Rysz A, Lawinski J, Rysz J. The Impact of Aerobic Exercise on HDL Quantity and Quality: A Narrative Review. Int J Mol Sci. 2023 Feb 28;24(5):4653. doi: 10.3390/ijms24054653.
Reference Type
BACKGROUND
Becic T, Studenik C, Hoffmann G. Exercise Increases Adiponectin and Reduces Leptin Levels in Prediabetic and Diabetic Individuals: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Med Sci (Basel). 2018 Oct 30;6(4):97. doi: 10.3390/medsci6040097.
Reference Type
BACKGROUND
Wang Y, Shen L, Xu D. Aerobic exercise reduces triglycerides by targeting apolipoprotein C3 in patients with coronary heart disease. Clin Cardiol. 2019 Jan;42(1):56-61. doi: 10.1002/clc.23104. Epub 2018 Dec 21.
Reference Type
BACKGROUND
Momma H, Kawakami R, Honda T, Sawada SS. Muscle-strengthening activities are associated with lower risk and mortality in major non-communicable diseases: a systematic review and meta-analysis of cohort studies. Br J Sports Med. 2022 Jul;56(13):755-763. doi: 10.1136/bjsports-2021-105061. Epub 2022 Feb 28.
Reference Type
BACKGROUND
Nascimento W, Ferrari G, Martins CB, Rey-Lopez JP, Izquierdo M, Lee DH, Giovannucci EL, Rezende LFM. Muscle-strengthening activities and cancer incidence and mortality: a systematic review and meta-analysis of observational studies. Int J Behav Nutr Phys Act. 2021 May 29;18(1):69. doi: 10.1186/s12966-021-01142-7.
Reference Type
BACKGROUND
Parra-Soto S, Pell JP, Celis-Morales C, Ho FK. Absolute and relative grip strength as predictors of cancer: prospective cohort study of 445 552 participants in UK Biobank. J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):325-332. doi: 10.1002/jcsm.12863. Epub 2021 Dec 24.
Reference Type
BACKGROUND
Massy-Westropp NM, Gill TK, Taylor AW, Bohannon RW, Hill CL. Hand Grip Strength: age and gender stratified normative data in a population-based study. BMC Res Notes. 2011 Apr 14;4:127. doi: 10.1186/1756-0500-4-127.
Reference Type
BACKGROUND
Cristian A. The sit to stand test in cancer patients and survivors. J Clin Oncol. 2023;41(16_suppl):e24058-e24058. doi:10.1200/JCO.2023.41.16_suppl.e24058
Reference Type
BACKGROUND
Cristian A, Rubens M, Cristian C, Wang G, Mendez J. Characterization of Physical Function and Cancer-Related Physical Impairments in Hispanic Women With Breast Cancer: A Descriptive Study. Hisp Health Care Int. 2023 Dec;21(4):195-202. doi: 10.1177/15404153231183447. Epub 2023 Jun 20.
Reference Type
BACKGROUND
Brouha L. The Step Test: A Simple Method of Measuring Physical Fitness for Muscular Work in Young Men. Res Q Am Assoc Health Phys Educ Recreat. 1943;14(1):31-37. doi:10.1080/10671188.1943.10621204
Reference Type
BACKGROUND
White KR, Lu J, Ibrahim Z, Furth PA. Enabling exercise prescription for survivors of cancer. Sci Rep. 2021 May 5;11(1):9557. doi: 10.1038/s41598-021-89021-w.
Reference Type
BACKGROUND
Kang SJ, Ha GC, Ko KJ. Association between resting heart rate, metabolic syndrome and cardiorespiratory fitness in Korean male adults. J Exerc Sci Fit. 2017 Jun;15(1):27-31. doi: 10.1016/j.jesf.2017.06.001. Epub 2017 Jun 20.
Reference Type
BACKGROUND
Jiang X, Liu X, Wu S, Zhang GQ, Peng M, Wu Y, Zheng X, Ruan C, Zhang W. Metabolic syndrome is associated with and predicted by resting heart rate: a cross-sectional and longitudinal study. Heart. 2015 Jan;101(1):44-9. doi: 10.1136/heartjnl-2014-305685. Epub 2014 Sep 1.
Reference Type
BACKGROUND
Rogowski O, Steinvil A, Berliner S, Cohen M, Saar N, Ben-Bassat OK, Shapira I. Elevated resting heart rate is associated with the metabolic syndrome. Cardiovasc Diabetol. 2009 Oct 14;8:55. doi: 10.1186/1475-2840-8-55.
Reference Type
BACKGROUND
Gutierrez-Martinez L, Brellenthin AG, Lefferts EC, Lee DC, Sui X, Lavie CJ, Blair SN. Resting Heart Rate and Risk of Cancer Mortality. Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1072-1078. doi: 10.1158/1055-9965.EPI-20-1731. Epub 2021 Apr 7.
Reference Type
BACKGROUND
Saint-Maurice PF, Troiano RP, Bassett DR Jr, Graubard BI, Carlson SA, Shiroma EJ, Fulton JE, Matthews CE. Association of Daily Step Count and Step Intensity With Mortality Among US Adults. JAMA. 2020 Mar 24;323(12):1151-1160. doi: 10.1001/jama.2020.1382.
Reference Type
BACKGROUND
Paluch AE, Bajpai S, Bassett DR, Carnethon MR, Ekelund U, Evenson KR, Galuska DA, Jefferis BJ, Kraus WE, Lee IM, Matthews CE, Omura JD, Patel AV, Pieper CF, Rees-Punia E, Dallmeier D, Klenk J, Whincup PH, Dooley EE, Pettee Gabriel K, Palta P, Pompeii LA, Chernofsky A, Larson MG, Vasan RS, Spartano N, Ballin M, Nordstrom P, Nordstrom A, Anderssen SA, Hansen BH, Cochrane JA, Dwyer T, Wang J, Ferrucci L, Liu F, Schrack J, Urbanek J, Saint-Maurice PF, Yamamoto N, Yoshitake Y, Newton RL Jr, Yang S, Shiroma EJ, Fulton JE; Steps for Health Collaborative. Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts. Lancet Public Health. 2022 Mar;7(3):e219-e228. doi: 10.1016/S2468-2667(21)00302-9.
Reference Type
BACKGROUND
Bosseboeuf A, Allain-Maillet S, Mennesson N, Tallet A, Rossi C, Garderet L, Caillot D, Moreau P, Piver E, Girodon F, Perreault H, Brouard S, Nicot A, Bigot-Corbel E, Hermouet S, Harb J. Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal Immunoglobulins. Front Immunol. 2017 Oct 19;8:1347. doi: 10.3389/fimmu.2017.01347. eCollection 2017.
Reference Type
BACKGROUND
Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MV. Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight. 2018 Apr 19;3(8):e98259. doi: 10.1172/jci.insight.98259. eCollection 2018 Apr 19.
Reference Type
BACKGROUND
Mitchell AM, Crane PA, Kim Y. Perceived stress in survivors of suicide: psychometric properties of the Perceived Stress Scale. Res Nurs Health. 2008 Dec;31(6):576-85. doi: 10.1002/nur.20284.
Reference Type
BACKGROUND
Roberti JW, Harrington LN, Storch EA. Further Psychometric Support for the 10-Item Version of the Perceived Stress Scale. J Coll Couns. 2006;9(2):135-147. doi:10.1002/j.2161-1882.2006.tb00100.x
Reference Type
BACKGROUND
Wu SM, Amtmann D. Psychometric Evaluation of the Perceived Stress Scale in Multiple Sclerosis. ISRN Rehabil. 2013;2013:1-9. doi:10.1155/2013/608356
Reference Type
BACKGROUND
Kloter E, Barrueto K, Klein SD, Scholkmann F, Wolf U. Heart Rate Variability as a Prognostic Factor for Cancer Survival - A Systematic Review. Front Physiol. 2018 May 29;9:623. doi: 10.3389/fphys.2018.00623. eCollection 2018.
Reference Type
BACKGROUND
Tegegne BS, Man T, van Roon AM, Snieder H, Riese H. Reference values of heart rate variability from 10-second resting electrocardiograms: the Lifelines Cohort Study. Eur J Prev Cardiol. 2020 Dec;27(19):2191-2194. doi: 10.1177/2047487319872567. Epub 2019 Sep 9. No abstract available.
Reference Type
BACKGROUND
Holt-Lunstad J. Loneliness and Social Isolation as Risk Factors: The Power of Social Connection in Prevention. Am J Lifestyle Med. 2021 May 6;15(5):567-573. doi: 10.1177/15598276211009454. eCollection 2021 Sep-Oct.
Reference Type
BACKGROUND
Lubben JE. Assessing social networks among elderly populations: Fam Community Health. 1988;11(3):42-52. doi:10.1097/00003727-198811000-00008
Reference Type
BACKGROUND
Yang M, Zhang Z, Nice EC, Wang C, Zhang W, Huang C. Psychological intervention to treat distress: An emerging frontier in cancer prevention and therapy. Biochim Biophys Acta Rev Cancer. 2022 Jan;1877(1):188665. doi: 10.1016/j.bbcan.2021.188665. Epub 2021 Dec 9.
Reference Type
BACKGROUND
Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med. 2010 Nov;40(11):1797-810. doi: 10.1017/S0033291709992285. Epub 2010 Jan 20.
Reference Type
BACKGROUND
Macek P, Biskup M, Terek-Derszniak M, Stachura M, Krol H, Gozdz S, Zak M. Optimal Body Fat Percentage Cut-Off Values in Predicting the Obesity-Related Cardiovascular Risk Factors: A Cross-Sectional Cohort Study. Diabetes Metab Syndr Obes. 2020 May 12;13:1587-1597. doi: 10.2147/DMSO.S248444. eCollection 2020.
Reference Type
BACKGROUND
Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ 3rd, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Norgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019 Aug;42(8):1593-1603. doi: 10.2337/dci19-0028. Epub 2019 Jun 8.
Reference Type
BACKGROUND
Advani A. Positioning time in range in diabetes management. Diabetologia. 2020 Feb;63(2):242-252. doi: 10.1007/s00125-019-05027-0. Epub 2019 Nov 7.
Reference Type
BACKGROUND
Liu Y, Pettersson E, Schandl A, Markar S, Johar A, Lagergren P. Dispositional optimism and all-cause mortality after esophageal cancer surgery: a nationwide population-based cohort study. Support Care Cancer. 2022 Nov;30(11):9461-9469. doi: 10.1007/s00520-022-07311-z. Epub 2022 Aug 11.
Reference Type
BACKGROUND
Thong MS, Kaptein AA, Vissers PA, Vreugdenhil G, van de Poll-Franse LV. Illness perceptions are associated with mortality among 1552 colorectal cancer survivors: a study from the population-based PROFILES registry. J Cancer Surviv. 2016 Oct;10(5):898-905. doi: 10.1007/s11764-016-0536-5. Epub 2016 Mar 19.
Reference Type
BACKGROUND
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.
Reference Type
BACKGROUND
Mielnik M, Szudy-Szczyrek A, Homa-Mlak I, Mlak R, Podgajna-Mielnik M, Goracy A, Malecka-Massalska T, Hus M. The Clinical Relevance of Selected Cytokines in Newly Diagnosed Multiple Myeloma Patients. Biomedicines. 2023 Nov 9;11(11):3012. doi: 10.3390/biomedicines11113012.
Reference Type
BACKGROUND
Nachbaur DM, Herold M, Maneschg A, Huber H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol. 1991 Feb-Mar;62(2-3):54-8. doi: 10.1007/BF01714900.
Reference Type
BACKGROUND
Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood. 1991 Jun 15;77(12):2794-5. No abstract available.
Reference Type
BACKGROUND
Jasrotia S, Gupta R, Sharma A, Halder A, Kumar L. Cytokine profile in multiple myeloma. Cytokine. 2020 Dec;136:155271. doi: 10.1016/j.cyto.2020.155271. Epub 2020 Sep 8.
Reference Type
BACKGROUND
Esmaeilzadeh Z, Kheradmand F, Rasmi Y, Khadem-Ansari M. Serum levels of IL-6, TNF-α, and YKL-40 in patients with stage I multiple myeloma. J Res Appl Basic Med Sci Res Appl Basic Med Sci. 2020;6(3):160-166.
Reference Type
BACKGROUND
Gu J, Huang X, Zhang Y, Bao C, Zhou Z, Jin J. Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels. Cytokine. 2021 Feb;138:155358. doi: 10.1016/j.cyto.2020.155358. Epub 2020 Nov 10.
Reference Type
BACKGROUND
Tsubaki M, Komai M, Itoh T, Imano M, Sakamoto K, Shimaoka H, Ogawa N, Mashimo K, Fujiwara D, Takeda T, Mukai J, Sakaguchi K, Satou T, Nishida S. Inhibition of the tumour necrosis factor-alpha autocrine loop enhances the sensitivity of multiple myeloma cells to anticancer drugs. Eur J Cancer. 2013 Nov;49(17):3708-17. doi: 10.1016/j.ejca.2013.07.010. Epub 2013 Aug 7.
Reference Type
BACKGROUND
Spath F, Wibom C, Krop EJM, Santamaria AI, Johansson AS, Bergdahl IA, Hultdin J, Vermeulen R, Melin B. Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples. Haematologica. 2019 Dec;104(12):2456-2464. doi: 10.3324/haematol.2019.216895. Epub 2019 Apr 4.
Reference Type
BACKGROUND
Ribas C, Colleoni GW, Felix RS, Regis Silva MR, Caballero OL, Brait M, Bordin JO. p16 gene methylation lacks correlation with angiogenesis and prognosis in multiple myeloma. Cancer Lett. 2005 May 26;222(2):247-54. doi: 10.1016/j.canlet.2004.09.038. Epub 2004 Nov 11.
Reference Type
BACKGROUND
Gkotzamanidou M, Christoulas D, Souliotis VL, Papatheodorou A, Dimopoulos MA, Terpos E. Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma. Med Sci Monit. 2013 Dec 20;19:1188-94. doi: 10.12659/MSM.889752.
Reference Type
BACKGROUND
Palta A, Kaur M, Tahlan A, Dimri K. Evaluation of Angiogenesis in Multiple Myeloma by VEGF Immunoexpression and Microvessel Density. J Lab Physicians. 2020 Mar;12(1):38-43. doi: 10.1055/s-0040-1714933. Epub 2020 Jul 24.
Reference Type
BACKGROUND
Rapp K, Schroeder J, Klenk J, Ulmer H, Concin H, Diem G, Oberaigner W, Weiland SK. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia. 2006 May;49(5):945-52. doi: 10.1007/s00125-006-0207-6. Epub 2006 Mar 24.
Reference Type
BACKGROUND
Tentolouris A, Ntanasis-Stathopoulos I, Eleftheriadou I, Malandrakis P, Tzeravini E, Gavriatopoulou M. Diabetes mellitus and multiple myeloma; common features of two distinct entities. Diabetes Metab Res Rev. 2022 Jul;38(5):e3535. doi: 10.1002/dmrr.3535. Epub 2022 May 25.
Reference Type
BACKGROUND
Thordardottir M, Lindqvist EK, Lund SH, Costello R, Burton D, Korde N, Mailankody S, Eiriksdottir G, Launer LJ, Gudnason V, Harris TB, Landgren O, Kristinsson SY. Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. Blood Adv. 2017 Nov 1;1(24):2186-2192. doi: 10.1182/bloodadvances.2017007609. eCollection 2017 Nov 14.
Reference Type
BACKGROUND
Liu L, Grandhi N, Wang M, et al. Association between excess body mass index trajectory and change in monoclonal protein level in patients diagnosed with monoclonal gammopathy of undetermined significance. J Clin Oncol. 2023;41(16_suppl):10538-10538. doi:10.1200/JCO.2023.41.16_suppl.10538
Reference Type
BACKGROUND
Wallin A, Larsson SC. Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies. Eur J Cancer. 2011 Jul;47(11):1606-15. doi: 10.1016/j.ejca.2011.01.020. Epub 2011 Feb 25.
Reference Type
BACKGROUND
Veld J, O'Donnell EK, Reagan MR, Yee AJ, Torriani M, Rosen CJ, Bredella MA. Abdominal adipose tissue in MGUS and multiple myeloma. Skeletal Radiol. 2016 Sep;45(9):1277-83. doi: 10.1007/s00256-016-2425-4. Epub 2016 Jun 25.
Reference Type
BACKGROUND
Teras LR, Kitahara CM, Birmann BM, Hartge PA, Wang SS, Robien K, Patel AV, Adami HO, Weiderpass E, Giles GG, Singh PN, Alavanja M, Beane Freeman LE, Bernstein L, Buring JE, Colditz GA, Fraser GE, Gapstur SM, Gaziano JM, Giovannucci E, Hofmann JN, Linet MS, Neta G, Park Y, Peters U, Rosenberg PS, Schairer C, Sesso HD, Stampfer MJ, Visvanathan K, White E, Wolk A, Zeleniuch-Jacquotte A, de Gonzalez AB, Purdue MP. Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. Br J Haematol. 2014 Sep;166(5):667-76. doi: 10.1111/bjh.12935. Epub 2014 May 23.
Reference Type
BACKGROUND
Makris A, Pagkali A, Nikolousis E, Filippatos TD, Agouridis AP. High-density lipoprotein cholesterol and multiple myeloma: A systematic review and meta-analysis. Atheroscler Plus. 2023 Sep 21;54:7-13. doi: 10.1016/j.athplu.2023.09.003. eCollection 2023 Dec.
Reference Type
BACKGROUND
Tavori H, Ormseth MJ, Lilley JS, Papen CR, May-Zhang LS, Davies SS, Linton MF, Fazio S. Progressively decreasing plasma high-density lipoprotein cholesterol levels preceding diagnosis of smoldering myeloma. J Clin Lipidol. 2020 May-Jun;14(3):293-296. doi: 10.1016/j.jacl.2020.04.001. Epub 2020 Apr 13.
Reference Type
BACKGROUND
Liang L, Li J, Fu H, Liu X, Liu P. Identification of High Serum Apolipoprotein A1 as a Favorable Prognostic Indicator in Patients with Multiple Myeloma. J Cancer. 2019 Aug 27;10(20):4852-4859. doi: 10.7150/jca.31357. eCollection 2019.
Reference Type
BACKGROUND
Yazdani R, Marefati H, Shahesmaeili A, Nakhaei S, Bagheri A, Dastoorpoor M. Effect of Aerobic Exercises on Serum Levels of Apolipoprotein A1 and Apolipoprotein B, and Their Ratio in Patients with Chronic Obstructive Pulmonary Disease. Tanaffos. 2018 Feb;17(2):82-89.
Reference Type
BACKGROUND
Hofmann JN, Mailankody S, Korde N, Wang Y, Tageja N, Costello R, Zingone A, Hultcrantz M, Pollak MN, Purdue MP, Landgren O. Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease. Obesity (Silver Spring). 2017 Aug;25(8):1317-1320. doi: 10.1002/oby.21894. Epub 2017 Jun 11.
Reference Type
BACKGROUND
Fowler JA, Lwin ST, Drake MT, Edwards JR, Kyle RA, Mundy GR, Edwards CM. Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood. 2011 Nov 24;118(22):5872-82. doi: 10.1182/blood-2011-01-330407. Epub 2011 Sep 8.
Reference Type
BACKGROUND
Dalamaga M, Christodoulatos GS. Adiponectin as a biomarker linking obesity and adiposopathy to hematologic malignancies. Horm Mol Biol Clin Investig. 2015 Jul;23(1):5-20. doi: 10.1515/hmbci-2015-0016.
Reference Type
BACKGROUND
Kriketos AD, Gan SK, Poynten AM, Furler SM, Chisholm DJ, Campbell LV. Exercise increases adiponectin levels and insulin sensitivity in humans. Diabetes Care. 2004 Feb;27(2):629-30. doi: 10.2337/diacare.27.2.629. No abstract available.
Reference Type
BACKGROUND
Vuong E, Nothling J, Lombard C, Jewkes R, Peer N, Abrahams N, Seedat S. Peripheral adiponectin levels in anxiety, mood, trauma- and stressor-related disorders: A systematic review and meta-analysis. J Affect Disord. 2020 Jan 1;260:372-409. doi: 10.1016/j.jad.2019.09.050. Epub 2019 Sep 11.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro2024-0235
Identifier Type: OTHER
Identifier Source: secondary_id
MGUS-SM-Lifestyle
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Strength Training in Improving Pain and Quality of Life in Patients With Multiple Myeloma
NCT03793907
COMPLETED
NA
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
NCT07225738
NOT_YET_RECRUITING
MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey
NCT04727294
UNKNOWN
The Ambient Light Multiple Myeloma Study
NCT05737732
RECRUITING
NA
Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes
NCT00809575
UNKNOWN
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
NCT05640843
RECRUITING
NA
Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma
NCT03068637
COMPLETED
NA
Inflammatory Cytokines in Symptom Production in Multiple Myeloma
NCT00688168
COMPLETED
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
NCT02030964
COMPLETED
PHASE1
Lymfit to Improve the Fitness and Quality of Life in Lymphoma Survivors
NCT05257785
RECRUITING
NA
Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma
NCT00242827
TERMINATED
PHASE2
Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients
NCT06250335
ACTIVE_NOT_RECRUITING
PHASE2
The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
NCT06228794
RECRUITING
Correlative Biomarker Study in Patients With Myeloproliferative Disorders
NCT00665067
COMPLETED
Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients
NCT01269203
WITHDRAWN
PHASE2
Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma
NCT00503763
WITHDRAWN
PHASE2
Refine and Assess the Readability of Patient, Carer, and Clinician Treatment Preference in Myelodysplasia Questionnaire
NCT05817331
COMPLETED
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
NCT00002850
COMPLETED
PHASE3
A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma
NCT02157636
COMPLETED
PHASE1
Examination of Trends in Multiple Myeloma Trial Patient Experiences
NCT05860179
NOT_YET_RECRUITING
CC-4047 in Treating Patients With Myelofibrosis
NCT00669578
COMPLETED
PHASE1/PHASE2
S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911
NCT00896922
COMPLETED
Prevention of Treatment Induced Neuropathy in Multiple Myeloma
NCT01283997
COMPLETED
PHASE2
Autoimmunity After Checkpoint Blockade
NCT04119713
RECRUITING
Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCT
NCT04685525
WITHDRAWN
NA